Skip to main content
. Author manuscript; available in PMC: 2011 Jan 21.
Published in final edited form as: J Magn Reson Imaging. 2007 Dec;26(6):1618–1625. doi: 10.1002/jmri.21196

Figure 1.

Figure 1

60 mice bearing equal sized BT474 tumors were randomized into 6 groups and treated according to 6 treatment arms as indicated. Paclitaxel was administered at the fixed standard dose of 30 mg/kg given once per week. A) control arm received vehicle oral gavage daily, B) daily gefitinib+paclitaxel arm received gefitinib at 60 mg/kg daily. This is the MTD for daily gefitinib in this combination. C) Single agent daily gefitinib arm received gefitinib at 150 mg/kg daily. This is the MTD for single agent gefitinib. D) Paclitaxel alone arm received vehicle oral gavage daily. E) pulse gefitinib+paclitaxel arm received gefitinib for two days each week at 250 mg/kg followed by paclitaxel on the third day. This is the MTD for gefitinib in this combination. F) The pulse gefitinib alone arm received gefitinib for two days each week at 250 mg/kg. This arm is a no-paclitaxel control for arm E.